The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
本公开提供了具有式(I)的取代异噁唑羧酰胺化合物及其药学上可接受的盐和溶液,其中R1、R2、A、X和Z的定义如说明书所述。本公开还涉及使用式 I 的化合物治疗对 SMYD 蛋白如 SMYD3 或 SMYD2 的阻断有反应的紊乱。本公开的化合物尤其适用于治疗癌症。
DERIVES DE CARBAMATES D'ALKYL-HETEROCYCLES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
申请人:SANOFI
公开号:EP2356108A1
公开(公告)日:2011-08-17
ANDROGEN RECEPTOR MODULATING COMPOUNDS
申请人:Orion Corporation
公开号:EP2493858A1
公开(公告)日:2012-09-05
ISOXAZOLE CARBOXAMIDE COMPOUNDS
申请人:Epizyme, Inc.
公开号:EP3193603A1
公开(公告)日:2017-07-26
Isoxazole Carboxamide Compounds
申请人:EPIZYME, INC.
公开号:US20170190676A1
公开(公告)日:2017-07-06
The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R
1
, R
2
, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.